Organon (OGN) Insider Rochelle Lazarus Buys $240K of Stock
Rochelle Lazarus picked up 17,857 shares of Organon & Co. on June 12, 2026, adding to a coordinated round of insider purchases.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rochelle Lazarus bought 17,857 shares of Organon & Co. ($OGN) at an average price of $13.44, worth about $239,998.08, on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OGN is down 0.3% after 1 week, up 0.5% after 1 month and up 2.5% to date (from the $13.42 close on Jun 12, 2026).
OGN
Organon & Co.
Key Points
- Rochelle Lazarus purchased 17,857 shares of Organon & Co. (NYSE:OGN) at $13.44 each on June 12, 2026, totaling roughly $240,000.
- The stock changed hands near its 52-week peak on Tuesday, backed by a trailing P/E ratio of 17.5 and a forward P/E of 3.78.
- Lazarus was joined by five other company insiders who acquired identical share amounts on the exact same date.
Get $OGN trade alerts by text
We text you when insiders, Congress or big funds trade $OGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Organon & Co. alert may contain errors. Disclosures
Rochelle Lazarus Acquires Shares of Organon & Co.
Rochelle Lazarus picked up shares of Organon & Co. (NYSE:OGN) on June 12, 2026, adding to a coordinated round of buying from leadership. According to a regulatory filing with the SEC, Lazarus bought 17,857 shares at a uniform price of $13.44 per share. The transaction came to a total value of $239,998.08.
Wave of Insider Activity at Organon & Co.
The transaction did not happen in isolation, as Lazarus joined a group of five other company leaders who all acquired identical blocks of stock on the same day. Robert Essner, Alan Ezekowitz, Helene Gayle, Cynthia Patton, and Deborah Leone each picked up 17,857 shares at the exact same price of $13.44 per share, resulting in individual transaction values of $239,998.08 apiece.
Organon Stock Trades Near Highs
Shares of Organon changed hands at $13.44 on Tuesday, sitting just under the company's 52-week peak of $13.79. The drug maker carries a trailing P/E ratio of 17.54 and a forward P/E ratio of 3.78, while trading comfortably above its 200-day moving average of $10.59.
About Organon & Co.
Organon & Co. operates as a healthcare company that creates and distributes various medical products and prescription therapies globally. Its portfolio spans treatments for women's health, biosimilars for immunology and oncology, cardiovascular medications, respiratory therapies, and dermatology products. The Jersey City-based firm serves drug wholesalers, hospitals, clinics, and pharmacies worldwide.
What to Watch Next for Organon
Investors tracking the healthcare firm can look toward the next scheduled earnings report on November 9, 2026, for further details on financial performance. Insider transactions like these offer a look into how leadership views the business, though they reflect past decisions rather than future guarantees.
Related Filing Alerts
Source: Rochelle Lazarus's Form 4 filing on $OGN (Jun 12, 2026). Find the original filing: OGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts